



# Investor Presentation



May 2026



# Disclaimer and important notice

This presentation has been prepared by TruScreen Group Limited (TRU). This presentation has been prepared in relation to the offer of new shares in TRU (New Shares) by way of a:

- Placement to selected investors in certain jurisdictions (Placement); and
- A 1 for 5 Rights Entitlement Offer to TRU's eligible existing shareholders with an address in either New Zealand or Australia (Rights Offer),

under clause 19 of Schedule 1 of the Financial Markets Conduct Act 2013 (FMCA) in New Zealand and in accordance with the relief granted in Australian Securities and Investments Commission (ASIC) Instrument 23-0122 and ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 as amended by ASIC Instrument 25-0323 in Australia (together, the Offer).

## Information of a general nature:

This presentation contains summary information about TRU and its activities which is current as at the date of this presentation. The information in this presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in TRU or that would be required in a product disclosure statement for the purposes of the FMCA or a prospectus or other disclosure document for the purposes of Chapter 6D of the Australian Corporations Act 2001 (Cth) ("Australian Corporations Act"). The historical information in this presentation is, or is based upon, information that has been released to NZX Limited (NZX) and ASX Limited (ASX). This presentation should be read in conjunction with TRU's other periodic and continuous disclosure announcements, which are available at [www.nzx.com](http://www.nzx.com) and [www.asx.com.au](http://www.asx.com.au).

## NZX and ASX:

The New Shares will be quoted on the NZX Main Board following completion of each of the Placement and the Retail Offer, and an application will be made by TRU for the New Shares to be quoted on the ASX.

Neither NZX nor ASX accepts any responsibility for any statement in this presentation. NZX is a licensed market operator, and the NZX Main Board is a licensed market under the FMCA.

## Not financial product advice:

This presentation is for information purposes only and is not financial, investment or financial product advice or a recommendation to acquire TRU securities and has been prepared without taking into account the objectives, financial situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and consult a broker, solicitor, accountant and/or other professional adviser.

## Past performance:

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

## Future performance:

This presentation contains certain "forward-looking statements" such as indications of, and guidance on, future earnings and financial position and performance. Forward-looking statements can generally be identified by the use of forward-looking words such as 'projected', 'expect', 'anticipate', 'likely', 'intend', 'could', 'may', 'predict', 'plan', 'propose', 'believe', 'forecast', 'estimate', 'target', 'outlook', 'guidance' and other similar expressions within the meaning of securities laws of applicable jurisdictions, and include, but are not limited to future revenues, the timing of implementation of certain initiatives, growth strategies, the timetable of the Offer and the use of proceeds. The forward-looking statements contained in this presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of TRU, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. There can be no assurance that actual outcomes will not materially differ from these forward-looking statements. A number of important factors could cause actual results or performance to differ materially from the forward-looking statements, including the risk factors set out in this presentation. Investors should consider the forward-looking statements contained in this presentation in light of those disclosures.

# Disclaimer and important notice (Continued)

## Future performance (continued):

The forward-looking statements are based on information available to TRU as at the date of this presentation. Except as required by law or regulation (including the NZX and ASX Listing Rules) TRU undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. Indications of, and guidance on, future earnings or financial position or performance are also forward-looking statements. An investment in securities in TRU is subject to investment and other known and unknown risks, some of which are beyond the control of TRU. TRU does not guarantee any particular rate of return or the performance of TRU.

## Financial data:

All dollar values are in New Zealand dollars (NZ\$ or NZD) unless otherwise stated.

Investors should be aware that this presentation contains certain financial information and measures that are "non-GAAP financial information" under the New Zealand Financial Markets Authority Guidance Note on disclosing non-GAAP financial information, "non-IFRS financial information" under Regulatory Guide 230 on disclosing non-IFRS financial information published by ASIC and "non-GAAP financial measures" within the meaning of Regulation G, under the U.S. Securities Exchange Act of 1934, and, therefore, are not recognised under New Zealand equivalents to International Financial Reporting Standards (NZ IFRS) and International Financial Reporting Standards (IFRS). The disclosure of such non-IFRS/GAAP financial information and financial measures in the manner included in this Presentation would not be permissible in a registration statement under the U.S. Securities Act of 1933 (the U.S. Securities Act). The non-IFRS/non-GAAP financial information and financial measures do not have a standardised meaning prescribed by NZ IFRS, Australian Accounting Standards or IFRS, and therefore, may not be comparable to similarly titled measures presented by other entities, nor should they be construed as an alternative to other financial measures determined in accordance with NZ IFRS or IFRS. Although TRU believes the non-IFRS/non-GAAP financial information and financial measures provide useful information to users in measuring the financial performance and condition of TRU, investors are cautioned not to place undue reliance on any non-IFRS/non-GAAP financial information or financial measures included in this presentation.

## Pro forma financial information:

This presentation also contains pro forma historical financial information to show the impact of the Placement. The pro forma information has not been audited or reviewed by TRU's auditors. The pro forma financial information provided in this presentation is for illustrative purposes only and is not represented as being indicative of TRU's views on its future financial condition and/or performance. The pro forma financial information has been prepared on the basis set out in this presentation. Investors should note that the pro forma financial information has not been prepared in accordance with, and does not purport to comply with, Article 11 of Regulation S-X under the U.S. Securities Act.

## Not a registered offer document:

This presentation is not a product disclosure statement, prospectus or other disclosure document under New Zealand law, Australian law, or any other law (and will not be lodged with the Registrar of Financial Service Providers, New Zealand Companies Office, ASIC or any other regulator or exchange in New Zealand, Australia or any other jurisdiction). Such regulators take no responsibility for the contents of this presentation. Accordingly, this presentation may not contain all information which a prospective investor may require to make a decision whether to subscribe for New Shares and it does not contain all of the information which would otherwise be required by New Zealand law, Australian law or any other law to be disclosed in a regulated product disclosure statement, prospectus, or any other form of disclosure document. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction, including the United States (and will not be lodged with the U.S. Securities Exchange Commission).

Any decision to purchase New Shares in the Rights Offer should be made on the basis of the information to be contained in a separate offer document to be prepared and made available to eligible retail shareholders. The offer document for the Rights Offer will be available to eligible retail shareholders in New Zealand and Australia following its lodgement with NZX and ASX. Any eligible shareholder who wishes to apply for New Shares under the Rights Offer should review the offer document and apply in accordance with the instructions contained in the offer document or as otherwise communicated by TRU. This presentation does not constitute investment or financial advice (nor tax, accounting or legal advice) or any recommendation to acquire New Shares and does not and will not form any part of any contract for the acquisition of New Shares. The release, publication or distribution of this presentation (including an electronic copy) in jurisdictions outside New Zealand and Australia may be restricted by law and you should observe such restrictions and should seek your own advice on such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws (see the Foreign Selling Restrictions section of this presentation).

By attending or reading this presentation you represent, warrant and agree that you: (i) are entitled to and permitted under applicable laws and regulations to receive the information contained in this presentation in accordance with the restrictions as set out in this section of the presentation; (ii) will base any investment decisions solely on information released by TRU via NZX and ASX (including, in the case of the Rights Offer, the offer document for the Rights Offer), and (iii) agree to be bound by the limitations contained therein.

# Disclaimer and important notice (continued)

## Distribution of presentation:

This presentation (including an electronic copy) must not be distributed in any jurisdiction to the extent that its distribution in that jurisdiction is restricted or prohibited by law or would constitute a breach by TRU of any law. The distribution of this presentation in other jurisdictions outside New Zealand or Australia may be restricted by law, and persons into whose possession this presentation comes should observe any such restrictions. Any failure to comply with such restrictions may violate applicable securities laws. None of TRU, any person named in this presentation or any of their affiliates accept or shall have any liability to any person in relation to the distribution or possession of this presentation from or in any jurisdiction.

## Not for distribution or release in the United States:

This presentation may not be released or distributed in the United States. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or any other jurisdiction in which such an offer would be illegal. The offer and sale of the New Shares have not been, and will not be, registered under the U.S. Securities Act or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable securities laws of any state or other jurisdiction of the United States.

## Eligibility:

Determination of eligibility of investors for the purposes of the Offer (or any part of the Offer) is determined by reference to a number of matters, including legal and regulatory requirements, logistical and registry constraints and the discretion of the underwriters and lead managers, and TRU. Each of the underwriters and lead managers and TRU and each of their respective related bodies corporate and affiliates, and each of their respective directors, officers, partners, employees, representatives and agents, disclaim any duty or liability in respect of that determination and the exercise or otherwise of that discretion, to the maximum extent permitted by law.

## Disclaimer:

To the maximum extent permitted by law, the lead managers, TRU, and their respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents exclude and disclaim all liability, for any direct or indirect expenses, losses, damages or costs incurred by you as a result of your participation in the Offer and/or the information in this presentation being inaccurate or incomplete in any way for any reason, whether in tort (including negligence), arising under statute, in contract or equity or otherwise. To the maximum extent permitted by law, the underwriters and lead managers and their respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents (Specified Persons) make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation and, with regards to each Specified Person, take no responsibility for any part of this presentation or the Offer. The Specified Persons make no recommendations as to whether you or your related parties should participate in the Offer nor do they make any representations or warranties to you concerning the Offer, and you represent, warrant and agree that you have not relied on any statements made by any of the Specified Persons in relation to the Offer and you further expressly disclaim that you are in a fiduciary relationship with any of them. You agree that you will not bring any proceedings against or hold or purport to hold any Specified Person liable in respect of this presentation or the information in this presentation and waive any rights you may otherwise have in this respect. Statements made in this presentation are made only as the date of this presentation. The information in this presentation remains subject to change without notice. TRU reserves the right to withdraw the Offer or vary the timetable for the Offer (whether for the Placement or the Rights Offer) without notice.

## General:

For the purposes of this Disclaimer and Important Notice, "presentation" means the slides, any oral presentation of the slides by TRU, any question-and-answer session that follows that oral presentation, hard copies of this presentation and any materials distributed at, or in connection with, that presentation.



- **Who is TruScreen**
- **The TruScreen Technology**
- **The Global Cervical Cancer Screening Market**
- **Why TruScreen**
- **TruScreen Sales and Growth Strategy**



# Who is TruScreen

**Enabled by AI, TruScreen provides an accurate, real time cervical cancer screening solution**



# TruScreen Group Ltd is a revenue generating Life Science company with a unique, AI-enabled real-time cervical cancer screening device.


FY26 annual sales exceeded NZD \$2.4m - 42% YOY growth.

TruScreen Group Ltd owns TruScreen Pty Ltd, the Australian operating company that manufactures and markets the TruScreen cervical cancer screening system.



# Share Price History

TRU.NZ



TruScreen Group Ltd is listed on the Australian (ASX) and New Zealand (NZX) stock exchanges, with a common ticker code of TRU.

**Market Capitalisation at 11 May 2026:**  
NZD \$13.45m

**Shares on Issue:**  
747,325,326




## Corporate Snapshot

Market cap	NZD\$ 13.45m
Share price	NZD\$ 0.018
52 week high	NZD\$ 0.030
52 week low	NZD\$ 0.016
Shares on issue	747,325,326
Options	<ul style="list-style-type: none"> <li>• 204,741,031 Exercisable at NZ\$0.022 with Expiry date 17 July 2026</li> <li>• 6,000,000 Exercisable at NZ\$0.04 with Expiry Date 15 July 2026</li> </ul>

## Major Shareholders

Shareholder	Shares	%
New Zealand Depository Nominee	110,486,503	14.78
New Zealand Central Securities	31,885,021	4.27
HSBC Custody Nominees	30,385,427	4.07
Masfen Securities Limited	29,050,369	3.89
Bhagwanji Bhula Rama	27,791,666	3.72
Ryan Peter Parkin	25,109,091	3.36
Kevin Ho & Vicki Ho	20,163,336	2.7

# The TruScreen Journey



# The Game Changer

1

The timeline compression of WHO's 90-70-90 milestones<sup>1</sup> to December 2030 - Sense of Urgency

2


UNITAID and global NGOs funding by late 2026 to drive cervical cancer screening



<sup>1</sup> <https://www.who.int/initiatives/cervical-cancer-elimination-initiative>

# Market Potential

**WHO 70%  
SCREENING  
TARGET**



	Malaysia	Thailand	China	Viet Nam	Mexico	Uzbekistan	Indonesia	India	Zimbabwe	South Africa	Eswatini	Nigeria	Kenya	Rwanda
■ Current screening coverage	40%	49%	28%	20%	35%	10%	7%	2%	18%	34%	12%	8%	7%	7%



Transformational opportunities have recently arisen through global funder **UNITAID's Call for Proposals: Accelerating Cervical Cancer Elimination through Secondary Prevention in Low and Middle Income Countries.**



Three grant applications have been made by TruScreen to UNITAID to screen an additional 400-500,000 women over 3 years.


If successful, additional public screening programs are estimated by TruScreen to add NZ\$4m to annual revenue from FY2028 to FY 2030.

TruScreen has also partnered with two global NGOs in separate grant applications to UNITAID for cervical screening programmes. In total, TruScreen is the technology partner in five grant applications to UNITAID.

# The TruScreen Technology



# How The TruScreen Device works



1

A pen-like wand covered by a Single Use Sensor (SUS) is used to gently touch multiple spots on the cervix. The SUS contains a precision lens and electrodes which interfaces with the cervix. In doing so, it sends and picks up low level electrical and optical signals (14 readings per second) from the cervical tissue.

2

The TruScreen Handheld Device then applies as an integrated AI-enabled algorithm to analyse these signals and compares them to an integrated database of 2,000 patients drawn from a wide range of geographic and ethnic backgrounds with differing histological diagnoses. This analysis identifies the presence of abnormal (cancerous and pre-cancerous) cells in the cervix and provides physicians with real-time results.

2 MINS

Each TruScreen examination takes one to two minutes to produce results, compared to conventional Pap tests which can take days, weeks, or even months in some countries, for a result to be returned.

## Instant results

TruScreen directly assesses the cervical tissue for precancerous and cancerous changes, and provides an **instant result during the patient visit.**

This **enables immediate counselling and clinical action.**

It does not rely on laboratory samples such as Pap smears or HPV tests and ensures equitable access to early detection.

By eliminating the need for laboratory infrastructure, consumables, and slide interpretation, TruScreen provides an efficient and objective triage solution, particularly valuable in low-resource settings facing significant barriers such laboratory dependence, high costs, infrastructure requirements, and loss to follow-up.



- ✓ Clinicians/physicians are able to **immediately plan appropriate patient care**
- ✓ Device has an expected life span of **5–7 years**
- ✓ Disposable SUS is used once per test per patient - ensures there is **no chance of cross-infection between patients**
- ✓ The entire patient data collection and analysis is self-checked and controlled. **No tissue sample needs to be taken.** These measures ensure that the results are reliable and consistent, and that the examination is painless and safe
- ✓ TruScreen has been **used on over 1 million women and there has never been a single adverse event reported**



# **The Global Cervical Cancer Screening Market**



# Cervical Cancer Is A Global Public Health Issue<sup>†</sup>

**Every 2 minutes**, a woman dies from cervical cancer.

**Fourth most common cancer** in women worldwide, but preventable - in fact only one of a handful of cancers that we understand fully.



**Most diagnoses occur at working age (35-44)**

Around **660,000 new cases** and around **350,000 deaths** in 2022 (WHO).

**94% of global deaths** occurred in low and middle income countries in 2022 (WHO).

# The Size of the Cervical Cancer Screening Market

- The global cervical cancer screening market is valued at **~USD 7.9 billion in 2024** - projected to reach **USD 14.5 billion by 2033**, an annual growth rate of 5.8% (CAGR).<sup>1</sup>
- **TruScreen currently makes up just 0.02% of the total market with enormous headroom for growth. In Low and Middle Income Countries alone, there are 1bn+ women of screening age.\***
- The market remains one of the most dynamic areas in preventive women’s healthcare, with technology, government support, and innovation driving its value higher each year.<sup>2</sup>
- Cervical cancer cases globally rose **16%** from 570,000 (2018) to 662,301 (2022), with **projections reaching over 1 million by 2050**.
- TruScreen’s three core markets of **China, India, and Indonesia** collectively account for 47.7% of all global cases.
- The WHO 70% screening target implies significant additional screening events needed, **predominantly in LMICs where TruScreen operates.**



<sup>1</sup> Zion Market Research

<sup>2</sup> Custom Market Insights

\*Women aged 15-64 years in the CIA World Fact Book : <https://www.cia.gov/the-world-factbook/>

# WHO & 194 Countries are committed to eliminating Cervical Cancer



World Health Organization



- In 2020 The World Health Organisation (WHO) and 194 member countries agreed on a strategy to eliminate cervical cancer this century

90%

90% HPV Vaccination coverage for girls by 15 years of age

70%

70% of women screened using a high-performance test by 35 years of age and again by 45 years of age


90%

90% of women with pre-cancer treated and 90% of women with invasive cancer managed

The WHO and member nations immediate commitment is to have screening coverage of 70% of women by 2030 – which TruScreen is well positioned to support.

# Why TruScreen






**FY26E  
Revenue**



**Devices operational  
worldwide**



**Women  
Screened**



**Active  
Countries**

- TruScreen operates in a favourable macro environment defined by the WHO 2030 **90-70-90** cervical cancer elimination strategy
- Unmet screening demand in low- and middle-income countries is significant, and TRU real-time technology is best suited to support screen-and-treat initiatives
- Adoption of AI-enabled point-of-care (POC) diagnostics is growing globally
- TruScreen holds less than 0.1% of the global cervical cancer screening market and 2.8% of the point-of-care device segment - headroom for growth is enormous

# Extensive body of clinical evidence

Over 40,000 women in clinical trials to date\*\*\*

Year	Country	Investigator	N
2002	China	Dr Huang Yi	683
2002	China	Dr Wang Ziyao	301
2003	UK/Aus	Prof A. Singer	651
2008	Poland	Dr. Pruski	234
2009	China	Prof Ding Ma	302
2010	China	Dr. He Xiu-Kui	392
2010	China	Prof Fengnian Rong	532
2010	Korea	Dr. Hyeong Soo Lim	292
2011	Poland	Dr. Pruski	293
2011	China	Dr. Li Xia	500
2015	Turkey	Dr. Özgü E	285
2016	China	Dr. LI Pei,	368
2017	Mexico	Dr. Ricardo Lua	521
2018	China	Dr. Huixia Yang	2730
2018-2021	China	54 Hospitals	14,982

Year	Country	Investigator	N
2019	China	Dr. Baojin Wang	315
2019	China	Dr. Wei Zhang	1030
2019	China	Dr. Yanhong Jia	320
2020	China	Dr Kang Yanan	192
2021	China	Prof Chen Fei	974
2021	China	Dr Wei Yingting	458
2022	China	Dr Chen Zhenbo	476
2022	China	Dr Zhu Bo	283
2022	China	Dr Zhao Yuqian	1319
2022	Australia	Dr Jessica Vet	506
2023	China	Dr Luo Lianmei	318
2023	China	Dr Liu Hang	997
2024	China	Dr Yang Yueming	489
2024	China	Dr Fengyi Xiao & Long Sui	1908
2024	Saudi Arabia	Dr S Maqsood and DrM Alhudhud	507

\*\*\*Total number of subjects across published and unpublished clinical studies in English, data from TruScreen device generation I and II



# COGA Trial (n= 14,982, 2018-2021) <sup>4</sup>

- COGA multicentre trial (64 hospitals, 9 provinces), represents **the world's largest opto-electronic cervical screening study**
- TruScreen specificity surpassed Liquid Based Cytology (LBC) and hrHPV
- TruScreen was determined to be a simple, effective and rapid real-time cervical cancer screening method
- TruScreen was determined to be an appropriate primary cervical cancer screening tool in regions with high morbidity and mortality to cervical cancer
- Highlighted the superiority of TruScreen against alternative screening methods as well as the potential benefits of a TruScreen-HPV co-testing.
- The size of the COGA study, which was TruScreen's largest clinical evaluation to date, lends extra significance to its results and broad conclusions.

## TruScreen's **sensitivity**

was well above that for LBC (87.5% v's 66.5%), with a high degree of statistical significance (p<0.001).

The sensitivity of TruScreen-hrHPV co-testing was higher than that of LBC-hrHPV co-testing, **98.4% vs 95.9%** (statistically significant at p=0.006).

## TruScreen's **specificity**

(88.4%) was higher than both LBC (86.3%) and hrHPV testing (78.3%) (also at p<0.001).

**NOTE:** A Saudi Study published in BMC Womens Health in April 2025 showed TS Sensitivity and Specificity of 83.3% and 95% v Pap at 66.7% and 98.2%

# Why TruScreen?

	TruScreen	Liquid Based Cytology (LBC)	HPV DNA
Real time results	✓		
Low infrastructure costs	✓		
Strong clinical results	✓	✓	✓
Objective results	✓		
Low training threshold	✓		
Portable	✓		
No cell or tissue samples taken	✓		

# **TruScreen Sales & Growth Strategy**



# Device installations and SUS Sales


KEY FINANCIALS NZD (m)	FY 23 Actual	FY 24 Actual	FY25 Actual	FY26 Actual (unaudited)
Sales	1.66	2.1	1.7	2.4
Total Revenue	2.2	2.6	2.1	2.8
COGS	1.3	1.4	1.2	1.7
R&D	0.9	0.9	0.8	0.9
EBITDA	-2.4	-2.0	-2.2	-2.2
Write off of Non-Current Assets	-0.05	-	-	-
Amortisation & Depreciation	-	-	-	-
LOSS FOR YEAR	-2.4	-2.0	-2.2	-2.2
Net Assets	2.5	3.2	1.0	2.6
Cash	2.2	2.7	0.04	1.5

## From FY25 to FY26:

- Sales increased 42% YOY
- SUS Sales increased 1% YOY
- Revenue increased 33% YOY
- EBITDA – no change YOY
- Net Assets increased 160% YOY
- China SUS/Device Pull Through -4% YOY


# FY25 ACTUAL

NZ\$1.7m



# FY26 ACTUAL

Unaudited sales NZ\$2.4m



# Recurring Revenue Model

- TruScreen manufactures two devices –
  - one made in China for use in China, where locally manufactured products have preferential market access
  - one made in Australia for other markets
- For each patient screened with the TruScreen device a new disposable Single Use Sensor (SUS) must be used. **This creates a recurring revenue model with a consumable sale for each patient screened with TruScreen.**

# TruScreen Sales Strategy

- Whilst many other medical technology companies seek to commercialize their devices in developed countries, **TruScreen focuses on Low and Middle Income Countries (LMICs) such as China, Mexico, Vietnam, India, Indonesia and Zimbabwe.**
- Working with global and national NGOs, to manage large scale public health screening programs
- These countries and other LMICs have no or minimal large-scale cervical cancer screening programs and infrastructure. This creates **a gap in the market** for TruScreen that is not available in the developed markets and allows quicker market access from a relative lack of existing competition.
- In comparison with cytology and HPV DNA screening **TruScreen is ‘capital light’**, not requiring lab infrastructure to be established prior to commencing screening.

# TruScreen Regulatory Approvals

## Recognized by

- World Health Organisation (WHO)
- UNITAID
- Clinton Health Access Initiative
- Daffodil Foundation - Australia
- China Obstetricians and Gynaecologists Association
- China Society for Colposcopy and Cervical Pathology
- Russia Cervical Cancer Screening Guideline
- Vietnam Hospital Technical List


## International Approvals:

- CE Mark, European Union
- NMPA, China
- TGA, Australia
- MHRA, UK
- SFDA, Saudi Arabia
- Roszdravnadzor, Russia
- COFEPRIS, Mexico
- WAND New Zealand
- Zimbabwe Ministry of Health
- IEAKI Indonesia
- Vietnam MOH
- India (Test Licence)
- Uzbekistan
- HSA, Singapore
- Thai FDA

## International Quality Accreditation:

- ISO 13485
- IEC 60601-1
- IEC 60601-1-2
- CE Mark

# Global presence



# Growth Strategies



Market expansion to continue with China the key focus



Focus on key growth provinces (Shandong, Jiangsu,, Hunan, Zhejiang, Guangdong, Guangxi) - Total population 496m



Enter huge African market collaborating with NGOs



Strengthen vertical Asian market from Indonesia through China, and capitalise on Indian distribution network



Target Govt and NGO funded programs in Zimbabwe, Vietnam, Mexico and Uzbekistan



**Build on International NGO Recognition (WHO, UNITAID, CHAI, COGA , CSCCP) to build acceptance and remove barriers to sale**



**Focus on countries with limited or nil cervical screening capability**



**Developing strategic partnerships for complementary woman's health services**



**Capitalise on global focus on AI enabled cervical cancer technologies – e.g. WHO**



**Expand product portfolio to include Dalton Bio HPV related IVD products, including HPV DNA tests and self sampling**



**Reduce SUS and Device COGS and increase margins**

# DaltonBio Strategic Alliance


- **Q4 FY25 - Memorandum of Understanding signed with Dalton Biosciences (DaltonBio)**
- **Q1 FY26 - TruScreen and Dalton Bio sign Distribution Agreement for HPV products in India**



1. TruScreen to be appointed a global distributor of DaltonBio HPV related IVD products (excluding U.S.A. and Canada).
2. DaltonBio to explore opportunities to assist sales of TruScreen's AI enabled real time cervical screening device within its distribution network, notably in its selected distributors in China and South America. DaltonBio have 200 sub distributors in China which may augment TruScreen's current distribution network in it's largest market.

The collaboration will enhance access to innovative cervical cancer screening and detection solutions by leveraging the technology strengths of both companies. As demonstrated in the COGA landmark study (2023) and Beijing Obstetrics and Gynecology Hospital study (Dovepress, May 2025), co-testing improved TruScreen's already impressive standalone sensitivity significantly.

# Thank you.




**Tony Ho**  
Executive Chairman

E – [tonyho@truscreen.com](mailto:tonyho@truscreen.com)

TruScreen  
Suite 3.03 18 Orion Rd  
Lane Cove West NSW 2066  
Australia

[www.truscreen.com](http://www.truscreen.com)



**Guy Robertson**  
Chief Financial Officer

E – [guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

